Dimerix Limited announced the current CEO, Kathy Harrison will transition to the newly created Chief Operating Officer role, with the major focus on running the DMX-200 Phase 2 trials. Through this new position, Ms. Harrison will continue to work directly with the Board with responsibility for execution of clinical development programs in addition to other activities normally associated with the COO position. Ms Harrison will continue in her incumbent CEO role until new CEO has been identified at which time the final step of organisational adjustment will take effect with Kathy assuming the COO role. Company announcement follows the news in late March that Associate Professor David Packham had been appointed as the Company's Chief Medical Officer.